Prosecution Insights
Browse Companies Examiners Firms Draft Your Response
Office Actions › Sanofi S.A. › 19392967
Last updated: July 12, 2026
Application No. 19/392,967

Untitled Application

Unknown
Filed
Priority
Sep 07, 2012 — provisional 61/697,972 +11 more
Examiner
MERTZ, PREMA MARIA
Art Unit
Tech Center
Sanofi Biotechnology
Assignee
Sanofi S.A.
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
Filing → Grant
99%
With Interview

Interview Optional

— +35.8% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 71% grant rate with +35.8% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.
Based on 760 resolved cases, 2023–2026

Examiner Intelligence

MERTZ, PREMA MARIA View full profile →
Grants 71% — above average
71%
Career Allowance Rate
543 granted / 760 resolved
+11.4% vs TC avg
Strong +36% interview lift
Without
With
+35.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
43 currently pending
Career history
786
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
39.4%
-0.6% vs TC avg
§102
10.3%
-29.7% vs TC avg
§112
37.2%
-2.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 760 resolved cases

Prosecution Timeline

Apr 21, 2026
Examiner Interview Summary
Apr 21, 2026
Applicant Interview (Telephonic)
Apr 21, 2026
Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/259,611
Patent 12674136
METHODS FOR PREPARING TUMOR-INFILTRATING LYMPHOCYTES
3y 0m to grant Granted Jul 07, 2026
18/259,205
Patent 12661402
POLYPEPTIDE SPECIFIC FOR MUCIN 1 AND USE THEREOF
3y 0m to grant Granted Jun 23, 2026
17/661,070
Patent 12655209
FcRn Antibodies and Methods of Use Thereof
4y 1m to grant Granted Jun 16, 2026
17/691,219
Patent 12655206
Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody
4y 3m to grant Granted Jun 16, 2026
17/734,482
Patent 12655207
SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIS WITH ANTI-IL-23 SPECIFIC ANTIBODY
4y 1m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+35.8%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 760 resolved cases by this examiner. Grant probability derived from career allowance rate.

Ready to respond to this office action?

IP Author drafts your complete OA response — amendments, arguments, and claim strategy — in minutes, not days.

Start Drafting Your Response →

Data sourced from USPTO Patent File Wrapper (daily) and Office Action Archive (weekly). Analysis generated by IP Author.

Data: USPTO Patent File Wrapper (daily) • Office Action Archive (weekly) • 89M+ prosecution events

© 2026 IP Author — Browse Office Actions • Examiners • Companies • Firms

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month